Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for recurrent aphthous ulceration
ChiCTR-IPR-17011608Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Stomatology, Sichuan University
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of thalidomide in aphthosis (RAS) (2 arms), sponsored by West China Hospital of Stomatology, Sichuan University. Primary endpoints: intermission and frequency of recurrence. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
aphthosis (RAS)
Beyond the preview
Go deeper on ChiCTR-IPR-17011608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011608.